-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The clinical manifestations of migraine are repeated episodes of moderate to severe headaches.
Without treatment intervention, the symptoms usually last for several hours to several days, accompanied by nausea and sensory disturbances
.
Recent studies have shown that 34.
FDA Prevention Researchers recently evaluated the efficacy and safety of Eptinezumab during migraine attacks
This study is a phase III, multi-center, parallel group, double-blind, randomized placebo-controlled trial, carried out in 47 centers in the United States, recruiting participants with a history of migraine for more than one year.
The patients are 18-75 years old.
During the 3 months before the screening , migraine attacks occurred for 4 to 15 days per month
.
Patients were randomized to receive 100 mg Eptinezumab (n=238) or placebo (n=242), and the treatment was completed within 1 to 6 hours after the onset of migraine
Screening
The average age of the patients was 44 years, 84% were women, and 476 people completed the study
.
Compared with placebo, Eptinezumab treatment significantly accelerated headache relief (average relief time: 4 hours vs.
Compared with placebo, Eptinezumab treatment significantly accelerated headache relief (average relief time: 4 hours vs.
No differences in headache and irritability symptoms between groups
Studies believe that for patients with moderate to severe migraine attacks, intravenous injection of Eptinezumab can shorten the headache time and accelerate the resolution of irritable symptoms
For patients with moderate to severe migraine attacks, intravenous injection of Eptinezumab can shorten the headache time and accelerate the resolution of irritable symptoms.
Original source:
Paul K.
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack A Randomized Clinical Trial.
JAMA Leave a message here
